Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 13/20 | 0.51 |
| ▸ | HTR2C | P28335 | 6/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5645330 | 0.99 | FAAH (0.52) | FAAHMCHR1HTR2CCHEK1 | |
| SCHEMBL5651127 | 0.84 | MCHR1 (0.66) | FAAHMCHR1HTR2CKDM4EALDH1A1 | |
| SCHEMBL5649106 | 0.82 | MCHR1 (0.68) | MCHR1HTR2CKDM4EALDH1A1 | |
| SCHEMBL5646136 | 0.82 | IRAK4 (0.47) | FAAHKDM4EALDH1A1 | |
| SCHEMBL5644296 | 0.81 | MCHR1 (0.69) | MCHR1HTR2CKDM4EALDH1A1 | |
| SCHEMBL14587877 | 0.81 | GAA (0.43) | FAAHKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5646561 | 0.80 | GAA (0.42) | FAAHKDM4EALDH1A1 | |
| SCHEMBL5646416 | 0.78 | PDGFRB (0.47) | FAAHMCHR1HTR2CPOLB | |
| SCHEMBL5648736 | 0.78 | MCHR1 (0.68) | FAAHMCHR1HTR2CKDM4EALDH1A1 | |
| SCHEMBL5645610 | 0.77 | MCHR1 (0.45) | FAAHMCHR1HTR2CPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050209213-A1 | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1447402-A1 | QUINOLINE COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209213-A1 | Quinoline compound | MC1R, MC2R, TYR | FAAH 591/4885MCHR1 4/4885HTR2C 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.